{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:02:34Z","timestamp":1791910954528,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00774-020-01097-y","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:03:46Z","timestamp":1586444626000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"1097_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE (2018) Hyperparathyroidism. Lancet 391:168\u2013178","journal-title":"Lancet"},{"key":"1097_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S, KRN1493 study group (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23:328\u2013335","journal-title":"Nephrol Dial Transplant"},{"key":"1097_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10:1031\u20131040","journal-title":"Clin J Am Soc Nephrol"},{"key":"1097_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135\u2013141","journal-title":"J Clin Endocrinol Metab"},{"key":"1097_CR5","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1210\/jc.2007-0585","volume":"92","author":"SJ Silverberg","year":"2007","unstructured":"Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803\u20133808","journal-title":"J Clin Endocrinol Metab"},{"key":"1097_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","volume":"35","author":"Y Takeuchi","year":"2017","unstructured":"Takeuchi Y, Takahashi S, Miura D, Katagiri M, Nakashima N, Ohishi H, Shimazaki R, Tominaga Y (2017) Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab 35:616\u2013622","journal-title":"J Bone Miner Metab"},{"key":"1097_CR7","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10:e1001436","journal-title":"PLoS Med"},{"key":"1097_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1177\/0091270007304103","volume":"47","author":"D Nakashima","year":"2007","unstructured":"Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, Uchida E, Tanaka H (2007) Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol 47:1311\u20131319","journal-title":"J Clin Pharmacol"},{"key":"1097_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","volume":"46","author":"RZ Harris","year":"2007","unstructured":"Harris RZ, Salfi M, Sullivan JT, Padhi D (2007) Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 46:495\u2013501","journal-title":"Clin Pharmacokinet"},{"key":"1097_CR10","doi-asserted-by":"publisher","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M (2018) A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE 13:e0195316","journal-title":"PLoS ONE"},{"key":"1097_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13434","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M (2019) Evocalcet, a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. https:\/\/doi.org\/10.1111\/1744-9987.13434(Epub ahead of print)","journal-title":"Ther Apher Dial"},{"key":"1097_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94:818\u2013825","journal-title":"Kidney Int"},{"key":"1097_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1530\/EJE-14-0877","volume":"172","author":"A Khan","year":"2015","unstructured":"Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, T\u00f3th M (2015) Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol 172:527\u2013535","journal-title":"Eur J Endocrinol"},{"key":"1097_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1359\/jbmr.081018","volume":"23","author":"C Marcocci","year":"2008","unstructured":"Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP (2008) Parathyroid carcinoma. J Bone Miner Res 23:1869\u20131880","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-020-01097-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:33:29Z","timestamp":1617924809000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-020-01097-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01097-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"24 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y Takeuchi, Y Imanishi, and S Fukumoto served as consultants for Kyowa Kirin Co., Ltd. Y Nishida and Y Kondo are employees of Kyowa Kirin Co., Ltd. The fund for the study and medical writing service was provided by Kyowa Kirin Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of each study institution and was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}